[How can tumor drug therapy be implemented in urooncology?].

Urologe A

Zertifiziertes Prostatakarzinom-Zentrum der Deutschen Krebsgesellschaft, Klinik für Urologie und Kinderurologie, St. Antonius-Hospital Eschweiler, 52249, Eschweiler, Germany.

Published: August 2008

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-008-1788-0DOI Listing

Publication Analysis

Top Keywords

[how tumor
4
tumor drug
4
drug therapy
4
therapy implemented
4
implemented urooncology?]
4
[how
1
drug
1
therapy
1
implemented
1
urooncology?]
1

Similar Publications

The incidence of keratinocyte carcinoma (KC) is rising globally, significantly burdening healthcare resources. Treatment options include medical treatment, non-invasive procedures, and surgery, each associated with their distinct benefits and risks. With advanced treatment, the procedures become increasingly invasive for the patients and expensive for the society.

View Article and Find Full Text PDF

Purpose: To develop and validate an MRI-based model for predicting postoperative early (≤2 years) recurrence-free survival (RFS) in patients receiving upfront surgical resection (SR) for beyond Milan hepatocellular carcinoma (HCC) and to assess the model's performance in separate patients receiving neoadjuvant therapy for similar-stage tumors.

Method: This single-center retrospective study included consecutive patients with resectable BCLC A/B beyond Milan HCC undergoing upfront SR or neoadjuvant therapy. All images were independently evaluated by three blinded radiologists.

View Article and Find Full Text PDF

Cell-Instructive Biomaterials with Native-Like Biochemical Complexity.

Annu Rev Biomed Eng

January 2025

1Weldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA; email:

Biochemical signals in native tissue microenvironments instruct cell behavior during many biological processes ranging from developmental morphogenesis and tissue regeneration to tumor metastasis and disease progression. The detection and characterization of these signals using spatial and highly resolved quantitative methods have revealed their existence as matricellular proteins in the matrisome, some of which are bound to the extracellular matrix while others are freely diffusing. Including these biochemical signals in engineered biomaterials can impart enhanced functionality and native-like complexity, ultimately benefiting efforts to understand, model, and treat various diseases.

View Article and Find Full Text PDF

Introduction: Sarcomas are a rare and diverse group of mesenchymal-origin solid tumors, constituting only 1% of adult malignancies and classified into soft tissue and bone sarcomas. For localized disease, surgery and radiotherapy remain the cornerstone treatments. However, systemic options for advanced stages are limited, with an overall survival of approximately 20 months.

View Article and Find Full Text PDF

Cystine-Modified Lignin-Copper Coordination Nanocarriers Improve the Therapeutic Efficacy of Tyrosine Kinase Inhibition via Cuproptosis.

ACS Appl Mater Interfaces

January 2025

Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, No. 651 Dongfeng Road East, Guangzhou, Guangdong 510060, P. R. China.

The clinical application of tyrosine kinase inhibitors (TKIs) is rapidly growing and has emerged as a cornerstone in the treatment of both solid tumors and hematologic malignancies. However, resistance to TKI targets and disease progression remain inevitable. Nanocarrier-mediated delivery has emerged as a promising strategy to overcome the limitations of the TKI application.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!